|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.92 SEK | -32.03% |
|
+16,507.70% | +13,658.62% |
| 06-15 | Immunovia Unveils New Data Ahead of Medicare Reimbursement Application | FW |
| 06-15 | Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage | CI |
Company Valuation: Immunovia AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,697 | 595.2 | 92.66 | 152.7 | 130.5 | - | - |
| Change | - | -64.93% | - | 64.79% | -14.54% | - | - |
| Enterprise Value (EV) 1 | 1,443 | 526.7 | 92.66 | 76.09 | 63.5 | 56.5 | 112.5 |
| Change | - | -63.5% | - | -17.88% | -16.55% | -11.02% | 99.12% |
| P/E | -0.11x | -0.04x | -0.01x | -0.54x | -1.94x | -4.85x | -9.7x |
| PBR | 0.04x | 0.02x | - | - | - | - | - |
| PEG | - | -0.01x | - | 0x | 0x | 0.1x | 0.2x |
| Capitalization / Revenue | 1,775x | 494x | - | 203x | 40.8x | 7.54x | 2.37x |
| EV / Revenue | 1,510x | 437x | - | 101x | 19.8x | 3.27x | 2.05x |
| EV / EBITDA | -9.78x | -3.17x | - | -0.97x | -0.71x | -0.71x | -2.39x |
| EV / EBIT | -8.66x | -2.76x | - | -0.95x | -0.7x | -0.69x | -2.25x |
| EV / FCF | -9.27x | -2.97x | - | -0.91x | -0.68x | -0.65x | -2.01x |
| FCF Yield | -10.8% | -33.6% | - | -110% | -148% | -154% | -49.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -689 | -743 | -93 | -0.42 | -0.1 | -0.04 | -0.02 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 0.956 | 1.204 | - | 0.752 | 3.2 | 17.3 | 55 |
| EBITDA 1 | -147.6 | -166.2 | - | -78.06 | -89 | -80 | -47 |
| EBIT 1 | -166.6 | -191.2 | - | -80.38 | -91 | -82 | -50 |
| Net income 1 | -156 | -168.1 | -76.54 | -145.9 | -91 | -82 | -50 |
| Net Debt 1 | -254.1 | -68.47 | - | -76.6 | -67 | -74 | -18 |
| Reference price 2 | 75.0000 | 26.3000 | 0.5460 | 0.2270 | 0.1940 | 0.1940 | 0.1940 |
| Nbr of stocks (in thousands) | 22,632 | 22,632 | 169,711 | 672,667 | 672,667 | - | - |
| Announcement Date | 2/17/22 | 2/23/23 | 2/25/25 | 2/24/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 59.15x | 4.76x | 15.91x | 0.36% | 16.36B | ||
| 41.7x | - | - | 1.94% | 1.78B | ||
| -11.41x | 1.33x | 5.85x | -.--% | 1.24B | ||
| 18.97x | 2.73x | 9.2x | 1.23% | 1.14B | ||
| 57.12x | - | - | 0.78% | 582M | ||
| 45.63x | - | - | - | 447M | ||
| 18.58x | 2.62x | 11.19x | 1.83% | 382M | ||
| 24.71x | 4.26x | 14.61x | 1.88% | 362M | ||
| Average | 31.81x | 3.14x | 11.35x | 1.15% | 2.79B | |
| Weighted average by Cap. | 50.19x | 4.37x | 14.76x | 0.58% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IMMNOV Stock
- 0G8X Stock
- Valuation Immunovia AB
Select your edition
All financial news and data tailored to specific country editions
















